Management of Anti-Tubercular Therapy-Induced Hepatitis

Immediate Management and Monitoring

The American Thoracic Society recommends stopping all hepatotoxic TB drugs immediately when liver enzymes exceed 3 times the upper limit of normal with hepatitis symptoms, or 5 times the upper limit of normal without symptoms, or when serum bilirubin exceeds the normal range 1, 2
Initiate a non-hepatotoxic holding regimen consisting of streptomycin and ethambutol to maintain anti-TB activity while liver function recovers 1
Exclude other causes of liver injury before attributing hepatotoxicity to anti-TB drugs, including viral hepatitis, biliary tract disease, alcohol, acetaminophen, lipid-lowering agents, and herbal supplements 1
Monitor liver function tests weekly for the first 2 weeks after each drug reintroduction, then every 2 weeks for the first 2 months 1, 2

For patients who cannot tolerate pyrazinamide, the Centers for Disease Control and Prevention recommends isoniazid, rifampin, and ethambutol for 2 months, followed by isoniazid and rifampin for 7 months (total 9 months) 3, 1, 4
If both isoniazid and pyrazinamide cannot be tolerated, the Infectious Diseases Society of America recommends rifampin, ethambutol, and a fluoroquinolone (levofloxacin 750-1000 mg daily or moxifloxacin 400 mg daily) for 12-18 months 3, 1
For patients with severe, unstable liver disease, the World Health Organization recommends ethambutol combined with a fluoroquinolone, cycloserine, and a second-line injectable for 18-24 months 3

Patients with pre-existing liver disease, chronic alcohol use, hepatitis B/C infection, HIV infection, malnutrition, or advanced age are at significantly higher risk for both initial hepatotoxicity and recurrence 1
These patients require more intensive monitoring and a lower threshold for drug discontinuation 1
Consider baseline hepatitis B and C screening for patients with injection drug use history, birth in Asia or Africa, or HIV infection 4

Monitor liver function tests at baseline and at 2, 4, 6, and 8 weeks during any regimen containing hepatotoxic drugs 5, 6, 2
Educate patients to stop medications immediately and seek medical attention if they develop abdominal pain, vomiting, jaundice, or other hepatitis symptoms 1
Avoid concurrent hepatotoxic medications, including over-the-counter drugs like acetaminophen 1